CytomX Therapeutics (CTMX) EPS (Basic): 2014-2025
Historic EPS (Basic) for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -$0.09.
- CytomX Therapeutics' EPS (Basic) fell 228.57% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.41, marking a year-over-year increase of 140.05%. This contributed to the annual value of $0.38 for FY2024, which is 3900.00% up from last year.
- As of Q3 2025, CytomX Therapeutics' EPS (Basic) stood at -$0.09, which was down 4,611.63% from -$0.00 recorded in Q2 2025.
- CytomX Therapeutics' EPS (Basic)'s 5-year high stood at $0.27 during Q1 2025, with a 5-year trough of -$0.53 in Q4 2021.
- Over the past 3 years, CytomX Therapeutics' median EPS (Basic) value was $0.01 (recorded in 2023), while the average stood at $0.05.
- Data for CytomX Therapeutics' EPS (Basic) shows a peak YoY increase of 2,200.00% (in 2024) and a maximum YoY decrease of 300.00% (in 2024) over the last 5 years.
- CytomX Therapeutics' EPS (Basic) (Quarterly) stood at -$0.53 in 2021, then spiked by 75.47% to -$0.13 in 2022, then soared by 107.69% to $0.01 in 2023, then skyrocketed by 2,200.00% to $0.23 in 2024, then tumbled by 228.57% to -$0.09 in 2025.
- Its EPS (Basic) stands at -$0.09 for Q3 2025, versus -$0.00 for Q2 2025 and $0.27 for Q1 2025.